Dr Jamie Tarbox, PHARMD in Clark, SD - Pharmacist

Dr Jamie Tarbox, PHARMD is a Pharmacist based in Clark, South Dakota. Dr Jamie Tarbox is licensed to practice in South Dakota (license number 5749) and her current practice location is 211 N Commercial St, Clark, South Dakota. She can be reached at her office (for appointments etc.) via phone at (605) 532-3400.

NPI number for Dr Jamie Tarbox is 1568978740 and her current mailing address is 211 N Commercial St, Clark, South Dakota. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1568978740.

Contact Information

	Dr Jamie Tarbox, PHARMD
	211 N Commercial St, Clark, SD 57225-1525
	(605) 532-3400
	Not Available

Healthcare Provider's Profile

Full Name	Dr Jamie Tarbox
Gender	Female
Speciality	Pharmacist
Location	211 N Commercial St, Clark, South Dakota
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1568978740
Provider Enumeration Date: 12/24/2017
Last Update Date: 02/28/2021

Medical Identifiers

Medical identifiers for Dr Jamie Tarbox such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1568978740	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	5749 (South Dakota)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Jamie Tarbox is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Jamie Tarbox, PHARMD 211 N Commercial St, Clark, SD 57225-1525 Ph: (605) 532-3400	Dr Jamie Tarbox, PHARMD 211 N Commercial St, Clark, SD 57225-1525 Ph: (605) 532-3400

News Archive

Community-based doulas dramatically increase breastfeeding rates in underserved communities

A new study by the federal government finds that community-based doulas – based on a program started by HealthConnect One – dramatically increase breastfeeding rates in underserved communities, where a baby's exposure to breast milk can help mitigate the impacts of poverty.

Monoclonal antibody treatment combo can reduce the impact of COVID-19 in high-risk patients

In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab - two monoclonal antibody treatments under Food and Drug Administration emergency use authorization - keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine.

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-DMPKRx. Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement.

Carbon monoxide poisoning easily detectable with Bedfont's ToxCO monitor

The ToxCO CO monitor has been designed by Bedfont, based in Kent, to safely and effectively screen patients for carbon monoxide poisoning. Known as the silent killer, CO is a colourless, odourless, highly poisonous gas that is produced when fuels are burned incompletely. Everybody is exposed to CO in everyday life; from boilers, open fires, cars, generators and even burning your toast.

Dr Jamie Tarbox, PHARMD - Pharmacist in Clark, SD